Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

To see complete record on, please visit this link

Id: NCT04433858

Organisation Name: Sheppard Pratt Health System

Overal Status: Active, not recruiting

Start Date: March 1, 2021

Last Update: December 20, 2022

Lead Sponsor: Sheppard Pratt Health System

Brief Summary: The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.

  • Treatment Resistant Depression

Total execution time in seconds: 0.28812694549561